VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL

Ryan Cassaday, MD, University of Washington, Seattle, WA, shares some preliminary results from a study evaluating the use of dose-adjusted EPOCH plus inotuzumab ozogamicin for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Dr Cassaday first highlights treatment approaches being evaluated for R/R B-ALL, and then discusses the response rates observed in this study. To conclude, Dr Cassaday comments on the overall safety, efficacy and adverse event profile of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding from Amgen, Kite/Gilead, Merck, Pfizer, Servier, and Vanda Pharmaceuticals; consulting/honoraria from Amgen, Kite/Gilead, and Pfizer; and spouse is employed by and owns stock in Seagen.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter